107 related articles for article (PubMed ID: 3928960)
41. [Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis].
Sawamura N; Funaki Y; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Yoshioka S; Sakurai M; Eguchi K
Gan To Kagaku Ryoho; 1985 Apr; 12(4):943-6. PubMed ID: 3885865
[TBL] [Abstract][Full Text] [Related]
42. Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy.
Navari RM; Province WS; Perrine GM; Kilgore JR
Cancer; 1993 Jul; 72(2):583-6. PubMed ID: 8319191
[TBL] [Abstract][Full Text] [Related]
43. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
Kenward H; Elliott J; Lee T; Pelligand L
BMC Vet Res; 2017 Aug; 13(1):244. PubMed ID: 28814338
[TBL] [Abstract][Full Text] [Related]
44. Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis.
Hellenbrecht D; Saller R
Arzneimittelforschung; 1986 Dec; 36(12):1845-9. PubMed ID: 3566848
[TBL] [Abstract][Full Text] [Related]
45. Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis.
Lehmann CR; Heironimus JD; Collins CB; O'Neil TJ; Pierson WP; Crowe JT; Melikian AP; Wright GJ
Clin Pharmacol Ther; 1985 Mar; 37(3):284-9. PubMed ID: 3971652
[TBL] [Abstract][Full Text] [Related]
46. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin.
Advani SH; Gopal R; Dhar AK; Lal HM; Cooverji ND
J Assoc Physicians India; 1996 Feb; 44(2):127-30. PubMed ID: 10999066
[TBL] [Abstract][Full Text] [Related]
47. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
Gebbia V; Testa A; Valenza R; Cannata G; Tirrito ML; Gebbia N
Cancer; 1995 Nov; 76(10):1821-8. PubMed ID: 8625054
[TBL] [Abstract][Full Text] [Related]
48. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
49. Metoclopramide versus metoclopramide and lorazepam. Superiority of combined therapy in the control of cisplatin-induced emesis.
Gordon CJ; Pazdur R; Ziccarelli A; Cummings G; Al-Sarraf M
Cancer; 1989 Feb; 63(3):578-82. PubMed ID: 2912533
[TBL] [Abstract][Full Text] [Related]
50. [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].
Nino S; Umehara H; Inoue I; Tamura T; Sasaki Y; Sakurai M; Shinkai T; Eguchi K; Saijo N; Suemasu K
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2881-4. PubMed ID: 3310905
[TBL] [Abstract][Full Text] [Related]
51. Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Support Care Cancer; 1994 May; 2(3):167-70. PubMed ID: 8032702
[TBL] [Abstract][Full Text] [Related]
52. [Antiemetic combination of metoclopramide and methylprednisolone for cisplatin-induced vomiting].
Saito H; Amano H; Yasuda Y; Tsunekawa H; Fujimoto K; Yoshii S; Shimokata K
Gan To Kagaku Ryoho; 1985 Oct; 12(10):1980-2. PubMed ID: 4051514
[TBL] [Abstract][Full Text] [Related]
53. Continuous infusion metoclopramide: clinical trials, pharmacokinetic considerations and cost-effectiveness.
Parashos PJ; Dugan WM; Fry MW
Prog Clin Biol Res; 1987; 248():303-11. PubMed ID: 3118389
[No Abstract] [Full Text] [Related]
54. Continuous infusion of metoclopramide for prevention of chemotherapy-induced emesis.
Agostinucci WA; Gannon RH; Schauer PK; Walters JK
Clin Pharm; 1986 Feb; 5(2):150-3. PubMed ID: 3956123
[No Abstract] [Full Text] [Related]
55. [Improved control of cisplatin-induced emesis with high-dose metoclopramide, dexamethasone and lorazepam].
Mau YK; Li YT; Tsui MS; Tu FC; Hsu KP
Zhonghua Yi Xue Za Zhi (Taipei); 1991 Feb; 47(2):116-20. PubMed ID: 1848133
[TBL] [Abstract][Full Text] [Related]
56. [Antiemetic effects of combinations of metoclopramide, droperidol and dexamethasone for the prevention of cisplatin-induced gastro-intestinal toxicity: a randomized crossover trial].
Fujii M; Kiura K; Kamei H; Okabe K; Toki H
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2257-61. PubMed ID: 3300561
[TBL] [Abstract][Full Text] [Related]
57. [Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis].
Dozono H; Ohmi K
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):454-7. PubMed ID: 3954370
[TBL] [Abstract][Full Text] [Related]
58. Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy.
Navari RM
J Clin Oncol; 1989 Jul; 7(7):943-6. PubMed ID: 2544688
[TBL] [Abstract][Full Text] [Related]
59. [Prevention of cytostatic-induced vomiting. High-dosage metoclopramide versus an antiemetic combination in a controlled comparison].
Ell C; König HJ; Gutmann W; Domschke S; Domschke W
Med Welt; 1983 Sep; 34(35):945-8. PubMed ID: 6355746
[No Abstract] [Full Text] [Related]
60. The pharmacokinetics of high dose metoclopramide in patients with neoplastic disease.
Bryson SM; McGovern EM; Kelman AW; White K; Addis GJ; Whiting B
Br J Clin Pharmacol; 1985 Jun; 19(6):757-66. PubMed ID: 4027119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
